Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
May 23, 2018
Cell Systems

Integration of genome-scale RNAi and CRISPR-Cas9 screens across cancer cell lines with large protein-protein interaction networks revealed novel protein complexes.

CTD²
May 22, 2018
Nature Communications

Scientists established a panel of patient-derived xenografts (PDXs) from subtypes of T-cell lymphomas (TCL) and cell lines for target validation and drug testing. Stapled peptide ALRN-6924 which blocks interactions between p53, MDM2 and MDMX showed pre-clinical activity against TCL lines and PDXs.

TARGET
May 21, 2018
Clinical Cancer Research

TARGET study associates RNA signatures of cytotoxic tumor-infiltrating lymphocytes with the presence of activated NK-/T-cells and suggests improved outcomes in newly diagnosed high-risk neuroblastoma patients with MYCN-NA tumor.

CTD²
May 14, 2018
Cancer Cell

Researchers performed an integrated analysis of TCGA genomic data and CPTAC proteomic data and demonstrated that A-to-I RNA editing contributes to proteomic diversity in breast cancer.

CTD²
May 11, 2018
Clinical Cancer Research

CTD2 scientists at Fred Hutchinson showed that the triplet combination of WEE1 tyrosine kinase inhibitor AZD1775, cisplatin, and docetaxel is safe and tolerable in a phase I clinical trial of head and neck cancer.

CTD²
May 03, 2018
Cell

CTD2 scientists at UTSW employed a chemistry-first approach to map the associations between chemicals and genetic lesions in lung cancer. These chemical vulnerabilities may reveal novel druggable targets for lung cancer.

CTD²
April 25, 2018
Cell Systems

Researchers at the UCSD CTD2 Center created a parsimonious composite network (PCNet), which has high efficiency and performance over any single network.

CTD²
April 24, 2018
Bioinformatics

Broad Institute CTD2 scientists developed a bioinformatic approach, RWEN, that predicts the responses of human cancer cell lines to a panel of compounds using the gene-expression profiles.

CTD²
April 17, 2018
Cell Reports

CTD2 researchers at UCSF-1 present a quantitative map linking the influence of chemotherapeutic agents to tumor genetics. This chemical-genetic interaction map can aid in identifying new factors that dictate responses to chemotherapy and prioritize drug combinations.

CTD²
April 16, 2018
Nature Communications

Scientists developed metaVIPER to assess protein activity in orphan tissues and single cells by integrative analysis of multiple, non-tissue-matched regulatory models. This approach could help to identify critical dependencies within molecularly heterogeneous sub-populations of cancer tissues.

Pages

XLS